Role of levosimendan in sepsis and septic shock

Current Opinion in Anaesthesiology

Volumn 21, Issue 2, 2008, Pages 168-177

  Pinto, Bernardo Bollen ^a,b   Rehberg, Sebastian ^a   Ertmer, Christian ^a   Westphal, Martin ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b HOSPITAL DE SANTO ANTÓNIO   (Portugal)

Author keywords

Global oxygen transport; Levosimendan; Myocardial dysfunction; Pulmonary circulation; Right ventricle; Sepsis; Septic shock

Indexed keywords

AMRINONE; CALCIUM; DOBUTAMINE; LEVOSIMENDAN; MILRINONE; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; PLACEBO; POTASSIUM CHANNEL; VASOPRESSIN; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACUTE HEART FAILURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIASTOLIC DYSFUNCTION; DIZZINESS; DRUG BINDING; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOTOXEMIA; HEADACHE; HEART FAILURE; HEART FUNCTION; HUMAN; HYPOTENSION; KIDNEY FUNCTION; LOADING DRUG DOSE; LUNG CIRCULATION; LUNG DISEASE; MYOCARDIAL DISEASE; NAUSEA; NONHUMAN; OXYGEN TRANSPORT; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; VASODILATATION; ANIMAL; DOSE RESPONSE; DRUG INTERACTION; METABOLISM;

ANIMALS; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENDOTOXEMIA; HEART FAILURE; HUMANS; HYDRAZONES; POTASSIUM CHANNELS; PYRIDAZINES; SEPSIS; SHOCK, SEPTIC;

EID: 43249121194     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e3282f43c56     Document Type: Review

References (93)

1. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554.
2. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC case mix programme database. Crit Care 2006; 10:R42.
3. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007; 35:1244-1250.
4. Lever A, Mackenzie I. Sepsis: definition, epidemiology, and diagnosis. Br Med J 2007; 335:879-883.
5. Annane D, Aegerter P, Jars-Guincestre MC, et al. Current epidemiology of septic shock: the UB-Rea Network. Am J Respir Crit Care Med 2003; 168:165-172.
6. Russell JA. Management of sepsis. N Engl J Med 2006; 355:1699-1713.
7. Rabuel C, Mebazaa A. Septic shock: a heart story since the 1960s. Intensive Care Med 2006; 32:799-807.
8. This review article summarizes current knowledge about sepsis-induced myocardial dysfunction.
9. Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 2007; 35:1599-1608.
10. This review article summarizes current knowledge about sepsis-induced myocardial dysfunction, with a particular focus on cellular pathophysiology and clinical studies.
11. Levy RJ, Clifford SD. Evaluating myocardial depression in sepsis. Shock 2004; 22:1-10.
12. Krishnagopalan S, Kumar A, Parrillo JE, Kumar A. Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care 2002; 8:376-388.
13. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360:196-202.
14. Mebazaa A, Barraud D, Welschbillig S. Randomized clinical trials with levosimendan. Am J Cardiol 2005; 96 (suppl): 74G-79G.
15. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure (The SURVIVE Randomized Trial). JAMA 2007; 297:1883-1891.
16. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European society of cardiology. Eur Heart J 2005; 26:384-416.
17. Chatti R, Fradj NB, Trabelsi W, et al. Algorithm for therapeutic management of acute heart failure syndromes. Heart Fail Rev 2007; 12:113-117.
18. Review article with an interesting proposal for an algorithm that may be applied in the management of AHFS.
19. Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev 2007; 12:149-156.
20. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, doubleblind study (RUSSLAN). Eur Heart J 2002; 23:1422-1432.
21. 2+- sensitization. Eur J Pharmacol 2004; 486:1-8.
22. Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of New Agents for Acute Heart Failure Syndromes. Am J Cardiol 2005; 96 (suppl): 68G-73G.
23. Jonsson EN, Antila S, McFadyen L, et al. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol 2003; 55:544-551.
24. Antila S, Kivikko M, Lehtonen L, et al. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol 2004; 57:412-415.
25. Mebazaa A, Cohen-Solal A, Kleber FX, et al. Levosimendan reduces mortality when compared with dobutamine in patients receiving beta blockers: The SURVIVE study. Intensive Care Med 2007; 33 (suppl 2): S92.
26. Rehberg S, Ertmer C, Van Aken H, et al. Role of levosimendan in intensive care treatment of myocardial insufficiency. Anaesthesist 2007; 56: 30-43.
27. Haikala H, Kaivola J, Nissinen E, et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995; 27:1859-1866.
28. Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: Interaction of levosimendan, a calcium sensitizer, with cardiac troponin c. Mol Cell Biochem 2004; 266:87-107.
29. Sugiura S. Actin-myosin interaction. Cardiovasc Res 1999; 44:266-273.
30. Haikala H, Nissinen E, Etemadzadeh E, et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995; 25:794-801.
31. Toller WG, Stranz C. Levosimendan, a New Inotropic and Vasodilator Agent. Anesthesiology 2006; 104:556-569.
32. Sato S, Talukder MAH, Sugawara H, et al. Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 1998; 30:1115-1128.
33. Takahashi R, Talukder MAH, Endoh M. Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium. J Cardiovasc Pharmacol 2000; 36:118-125.
34. 2+ transients under acidotic condition in aequorinloaded canine ventricular myocardium. Naunyn-Schmiedeberg's Arch Pharmacol 2002; 366:440-448.
35. Toller W, Wolkart G, Stranz C, et al. Contractile action of levosimendan and epinephrine during acidosis. Eur J Pharmacol 2005; 507:199-209.
36. Yokoshiki H, Yasuhiro K, Masanori S, Sperelakis N. The Novel Calcium Sensitizer Levosimendan Activates the ATP-Sensitive K1 Channel in Rat Ventricular Cells. J Pharmacol Exp Ther 1997; 283:375-383.
37. ATP channel opener. Eur J Pharmacol 2001; 428:311-314.
38. Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 2004; 68:807-812.
39. ATP channels. Anesth Analg 2000; 90:5-11.
40. Gross GJ, Peart JN. Katp channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol 2003; 285:921-930.
41. + Channels. J Pharmacol Sci 2007; 104:1-5.
42. Review article summarizing the evidence on the vasodilatory effects of levosimendan.
43. Ozdem SS, Yalcin O, Meiselman HJ, et al. The role of potassium channels in relaxant effect of levosimendan in rat small mesenteric arteries. Cardiovasc Drugs Ther 2006; 20:123-127.
44. Pataricza J, Krassói I, Höhn J, et al. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 2003; 17:115-121.
45. De Witt BJ, Ibrahim IN, Bayer E, et al. An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg 2002; 94:1427-1433.
46. Pataricza J, Hohn J, Petri A, et al. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 2000; 52:213-217.
47. Hohn J, Pataricza J, Petri A, et al. Levosimendan interacts with potassium channel blockers in human saphenous veins. Basic Clin Pharmacol Toxicol 2004; 94:271-273.
48. Yokoshiki H, Sperelakis N. Vasodilating mechanisms of levosimendan. Cardiovasc Drugs Ther 2003; 17:111-113.
49. Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1903-1912.
50. Morelli A, De Castro S, Teboul JL, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial dysfunction. Intensive Care Med 2005; 31:638-644.
51. Morelli A, Teboul JL, Maggiore SM, et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: A pilot study. Crit Care Med 2006; 34:2287-2293.
52. Clinical trial reporting beneficial effects of levosimendan on hemodynamics, global oxygen transport, pulmonary circulation and right ventricular dysfunction in septic shock patients with ARDS.
53. Westphal M, Morelli A, Van Aken H. Dear levosimendan, the right ventricular will thank you. Crit Care Med 2007; 35:952-953.
54. Kerbaul F, Rondelet B, Demester JP, et al. Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2006; 34:2814-2819.
55. Missant C, Rex S, Segers P, et al. Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction. Crit Care Med 2007; 35:707-715.
56. Kerbaul F, Gariboldi V, Giorgi R, et al. Effects of levosimendan on acute pulmonary embolism-induced right ventricular failure. Crit Care Med 2007; 35:1948-1954.
57. Sharma AC. Sepsis-induced myocardial dysfunction. Shock 2007; 28:265-269.
58. Review article detailing the role of endothelin-1 and cellular apoptosis in sepsisinduced myocardial dysfunction.
59. Silverman HJ, Penaranda R, Orens JB, Lee NH. Impaired β-adrenergic receptor stimulation of cyclic adenosine monophosphate in human septic shock: Association with myocardial responsiveness to catecholamines. Crit Care Med 1993; 21:31-39.
60. Abi-Gerges N, Tavernier B, Mebazaa A, et al. Sequential changes in autonomic regulation of cardiac myocytes after in vivo endotoxin injection in rat. Am J Respir Crit Care Med 1999; 160:1196-1204.
61. Macarthur H, Westfall TC, Riley DP, et al. Inactivation of catecholamines by superoxide gives new insights on the pathogenesis of septic shock. Proc Natl Acad Sci 2000; 97:9753-9758.
62. Tavernier B, Garrigue D, Boulle C, et al. Myofilament calcium sensitivity is decreased in skinned cardiac fibres of endotoxin-treated rabbits. Cardiovasc Res 1998; 38:472-479.
63. Tavernier B, Li JM, El-Omar MM, et al. Cardiac contractile impairment associated with increased phosphorylation of troponin I in endotoxemic rats. FASEB J 2001; 15:294-296.
64. Tavernier B, Mebazaa A, Mateo P, et al. Phosphorylation-dependent alteration in myofilament Ca2+ sensitivity but normal mitochondrial function in septic heart. Am J Respir Crit Care Med 2001; 163:362-367.
65. Oldner A, Konrad D, Weitzberg E, et al. Effects of levosimendan, a novel inotropic calcium sensitizing drug, in experimental septic shock. Crit Care Med 2001; 29:2185-2193.
66. Faivre V, Kaskos H, Callebert J, et al. Cardiac and renal effects of levosimendam, arginine vasopressin, and norepinephrine in lipopolysaccharidetreated rabbits. Anesthesiology 2005; 103:514-521.
67. Dubin A, Murias G, Sottile JP, et al. Effects of levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study. Intensive Care Med 2007; 33:485-494.
68. Cunha-Goncalves D, Perez-de-Sa V, Dahm P, et al. Cardiovascular effects of levosimendan in the early stages of endotoxemia. Shock 2007; 28:71-77.
69. De Backer D, Taccone FS, Radermacher P. Levosimendan in septic shock: another piece in the puzzle, but many pieces are still lacking. Intensive Care Med 2007; 33:403-405.
70. Behrends M, Peters J. The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts. Intensive Care Med 2003; 29:1802-1807.
71. Barraud D, Faivre V, Damy T, et al. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: Comparison with dobutamine and milrinone. Crit Care Med 2007; 35:1376-1382.
72. Elegantly designed endotoxic animal model that reports the specific effects of levosimendan on cardiac performance.
73. Zager RA, Johnson AC, Lund S, et al. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol 2006; 290:1453-1462.
74. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150.
75. Fiddian-Green RG. Associations between intramucosal acidosis in the gut and organ failure. Crit Care Med 1993; 21 (Suppl): S103-S107.
76. Rehberg S, Ertmer C, Lange M, et al. Levosimendan prolongs survival in ovine septic shock (abstract). Crit Care 2008; [in press]
77. This experimental study clearly shows that combined infusion of arginine vasopressin and levosimendan prolongs survival as compared to sole arginine vasopressin infusion.
78. Singer M. Catecholamine treatment for shock-equally good or bad? Lancet 2007; 370:636-637.
79. Matejovic M, Krouzecky A, Radej J, Novak I. Successful reversal of resistant hypodinamic septic shock with levosimendan. Acta Anaesthesiol Scand 2005; 49:127.
80. Noto A, Giacomini M, Palandi A, et al. Levosimendan in septic cardiac failure. Intensive Care Med 2005; 31:164-165.
81. Powell BP, De Keulenaer BL. Levosimendan in septic shock: a case series. Br J Anaesth 2007; 99:447-448.
82. Oliveira MT Jr, Follador W, Martins ML, et al. Cost analysis of the treatment of acute decompensated heart failure. Levosimendan versus dobutamine. Arq Bras Cardiol 2005; 85:9-14.
83. Cleland JG, Takala A, Apajasalo M, et al. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. Eur J Heart Fail 2003; 5:101-108.
84. Kaptan K, Erinç K, Ifran A, et al. Levosimendan has an inhibitory effect on platelet function. Am J Hematol 2007; [Epub ahead of print].
85. Parissis JT, Adamopoulos S, Antoniades C, et al. Effects of Levosimendan on Circulating Proinflammatory Cytokines and Soluble Apoptosis Mediators in Patients With Decompensated Advanced Heart Failure. Am J Cardiol 2004; 93:1309-1312.
86. 2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005; 7:882-887.
87. Adamopoulos S, Parissis JT, Iliodromitis EK, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006; 98:102-1 06.
88. Singer M. Mitochondrial function in sepsis: acute phase versus multiple organ failure. Crit Care Med 2007; 35:S441-S448.
89. Up-to-date comprehensive review on the role of mitochondrial dysfunction in sepsis.
90. Fink MP. Bench-to-bedside review: Cytopathic hypoxia. Crit Care 2002; 6:491-499.
91. ATP channels in sepsis. Cardiovasc Res 2006; 72:220-230.
92. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345:588-595.
93. Lange M, Morelli A, Ertmer C, et al. Role of adenosine triphosphate-sensitive potassium channel inhibition in shock states: physiology and clinical implications. Shock 2007; 28:394-400.